跳轉至內容
Merck
全部照片(1)

文件

G004366

HPLC Analysis of Verapamil and Metabolites in Rat Plasma on Ascentis® Express C18 after Phospholipid Removal using HybridSPE®-Phospholipid

application for SPE, application for LC-MS

登入查看組織和合約定價


About This Item

技術

LC/MS: suitable
solid phase extraction (SPE): suitable

測試參數

SPE well plate: HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U)
sample preparation: SPE (Solid Phase Extraction)
column: Ascentis Express C18, 5 cm x 2.1 mm I.D., 2.7 μm particles (53822-U)
sample/matrix: Rat plasma spiked with verapamil and metabolites at 10 ng/mL
mobile phase: [A] water; [B] acetonitrile, pH 2.55 adjust with formic acid (30:70, A:B)
flow rate: 0.6 mL/min
column temp.: 35 °C
detector: TOF/MS
injection: 1 μL
sample addition: 100 μL spiked rat plasma followed by 300 μL 1% formic acid in acetonitrile
elution: apply vacuum

適合性

application for LC-MS
application for SPE

應用

clinical

法律資訊

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務